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Background
Hyponatremia (serum sodium concentration, <135 mmol per liter) is a predictor of 
death among patients with chronic heart failure and cirrhosis. At present, therapy 
for acute and chronic hyponatremia is often ineffective and poorly tolerated. We 
investigated whether tolvaptan, an orally active vasopressin V2-receptor antagonist 
that promotes aquaresis — excretion of electrolyte-free water — might be of ben-
efit in hyponatremia.
Methods
In two multicenter, randomized, double-blind, placebo-controlled trials, the effi-
cacy of tolvaptan was evaluated in patients with euvolemic or hypervolemic hypo-
natremia. Patients were randomly assigned to oral placebo (223 patients) or oral 
tolvaptan (225) at a dose of 15 mg daily. The dose of tolvaptan was increased to 
30 mg daily and then to 60 mg daily, if necessary, on the basis of serum sodium 
concentrations. The two primary end points for all patients were the change in the 
average daily area under the curve for the serum sodium concentration from base-
line to day 4 and the change from baseline to day 30.
Results
Serum sodium concentrations increased more in the tolvaptan group than in the 
placebo group during the first 4 days (P<0.001) and after the full 30 days of therapy 
(P<0.001). The condition of patients with mild or marked hyponatremia improved 
(P<0.001 for all comparisons). During the week after discontinuation of tolvaptan 
on day 30, hyponatremia recurred. Side effects associated with tolvaptan included 
increased thirst, dry mouth, and increased urination. A planned analysis that com-
bined the two trials showed significant improvement from baseline to day 30 in the 
tolvaptan group according to scores on the Mental Component of the Medical Out-
comes Study 12-item Short-Form General Health Survey.
Conclusions
In patients with euvolemic or hypervolemic hyponatremia, tolvaptan, an oral vaso-
pressin V2-receptor antagonist, was effective in increasing serum sodium concentra-
tions at day 4 and day 30. (ClinicalTrials.gov numbers, NCT00072683 [SALT-1] and 
NCT00201994 [SALT-2].)
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H yponatremia, the most common electrolyte derangement occurring in hos-pitalized patients,1,2 is usually classified 
as hypovolemic, euvolemic, or hypervolemic. The 
secretion of arginine vasopressin appears to be 
of central importance in the decline of serum 
sodium concentrations in all these conditions.1,2 
Hyponatremia is reported to be associated with 
increased morbidity and mortality among patients 
with heart, liver, or neurologic disease.3-8 Even mild 
chronic hyponatremia has been associated with 
subtle neurologic defects, manifested as impair-
ments in balance and attention that can increase 
the incidence of falls.9 These deficits may be re-
versed with the correction of the hyponatremia.
Tolvaptan, a novel, orally active, selective, non-
peptide antagonist that blocks arginine vasopres-
sin from binding to V2 receptors of the distal 
nephron, induces the excretion of electrolyte-free 
water without changing the total level of electro-
lyte excretion.10 In patients with heart failure, 
tolvaptan appears to decrease body weight and 
edema and increase serum sodium concentrations 
without adversely affecting serum electrolyte lev-
els, vital signs, or renal function.11-14
We report the results of two randomized, pla-
cebo-controlled, double-blind phase 3 studies 
(Study of Ascending Levels of Tolvaptan in Hypo-
natremia 1 and 2 [SALT-1 and SALT-2]) examining 
the effect of tolvaptan on hypervolemic and eu-
volemic hyponatremia of diverse causes. These 
trials assessed the outpatient use of a vasopressin 
V2-receptor antagonist for hyponatremia of di-
verse origin, including assessments of reversibility 
and safety.
Me thods
Patients
Eligible patients were 18 years of age or older and 
had euvolemic or hypervolemic hyponatremia 
(defined as a nonartifactual serum sodium con-
centration of <135 mmol per liter). Patients had 
chronic heart failure, cirrhosis, or the syndrome 
of inappropriate antidiuretic hormone secretion 
(SIADH) in association with the hyponatremia. 
Persons with psychogenic polydipsia, head trauma, 
postoperative conditions, uncontrolled hypothy-
roidism or adrenal insufficiency, or any hypona-
tremic condition associated with the use of med-
ications that could have been safely withdrawn 
were ineligible. The study protocols required a 
serum sodium concentration of less than 130 mmol 
per liter at baseline in 50% of those enrolled and 
also required that no single disease entity be rep-
resented in more than half the total study popu-
lation. Mild hyponatremia was defined as 130 to 
134 mmol of sodium per liter and marked hypo-
natremia as less than 130 mmol of sodium per 
liter.
Patients were ineligible if they had clinically 
evident hypovolemic hyponatremia (a state in 
which normal plasma sodium concentrations 
could be reestablished through the restoration of 
plasma volume). Other exclusion criteria were re-
cent cardiac surgery, myocardial infarction, sus-
tained ventricular tachycardia or fibrillation, se-
vere angina, cerebrovascular accident, or multiple 
strokes; systolic blood pressure of less than 90 
mm Hg, central venous pressure of less than 5 cm 
of water, pulmonary-capillary wedge pressure of 
less than 5 mm Hg, a serum creatinine concen-
tration of more than 3.5 mg per deciliter (309 
μmol per liter), a Child–Pugh score of more than 
10 (unless approved by the study’s medical moni-
tor), or a serum sodium concentration less than 
120 mmol per liter in association with neurologic 
impairment; and the presence of severe pulmo-
nary hypertension, urinary tract obstruction, un-
controlled diabetes mellitus, or progressive or 
episodic neurologic disease. Patients who were 
judged to have little chance of short-term survival 
or who might not tolerate sudden shifts in fluid 
volumes or pressures were ineligible.
Study Design
The two trials were identical prospective, multi-
center, randomized, double-blind, placebo-con-
trolled efficacy studies that were conducted at 42 
sites in the United States between April 11, 2003, 
and December 20, 2005, and at 50 international 
sites between November 20, 2003, and July 6, 
2005. The identical study designs of the two tri-
als assessed reproducibility and were intended to 
ensure comparability. The institutional review 
board or ethics committee at each site approved 
the study protocols and ensured that written in-
formed consent was obtained from all patients.
Patients meeting the eligibility requirements 
underwent central randomization with the use of 
random permuted blocks and stratification ac-
cording to whether hyponatremia was mild or 
marked and whether or not it was associated with 
chronic heart failure. Patients were assigned in a 
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1:1 ratio to receive oral tolvaptan (a 15-mg tablet) 
or matching placebo once daily for up to 30 days. 
Study drugs were administered in the morning 
in either an inpatient or outpatient setting as an 
adjunct to the patient’s standard therapy. Fluid 
restriction was not mandatory according to the 
study protocol. Treatment of hyponatremia with 
demeclocycline, lithium chloride, or urea was not 
permitted.
During the initial 4 days of therapy, the dose 
of the study drug could be increased from 15 to 
30 mg or from 30 to 60 mg according to a regi-
men designed for slow correction of serum sodi-
um concentrations to 135 mmol per liter or more. 
If the serum sodium concentration remained be-
low 136 mmol per liter and had increased by less 
than 5 mmol per liter during the prior 24 hours, 
the dose was increased. If the serum sodium 
concentration rose above 145 mmol per liter or 
increased at too great a rate (by more than 12 
mmol per liter during 24 hours or by more than 
8 mmol per liter during 8 hours on the first day 
of therapy), the investigator either withheld or 
decreased the next dose or increased the pa-
tient’s fluid intake. Patients were hospitalized for 
the first day of the study; the majority were dis-
charged by day 4.
Study Assessments
Patients were evaluated at baseline, 8 hours after 
the first administration of the study drug (tolvap-
tan or placebo), and on days 2, 3, 4, 11, 18, 25, 
30, and 37. Study drugs were withheld after day 30, 
and the effect of discontinuation of the study drug 
was assessed on day 37.
The assessments included the two primary 
end points of the study: the change in the aver-
age daily area under the curve (AUC) for the se-
rum sodium concentration from baseline to day 
4 and from baseline to day 30. Prespecified sec-
ondary end points included the change in the 
AUC for the serum sodium concentration in pa-
tients with marked hyponatremia, the absolute 
serum sodium concentration at each visit, the time 
to normalization of the serum sodium concentra-
tion, the percentages of patients with serum so-
dium concentrations that had normalized at day 
4 and day 30, and the categorical serum sodium 
concentration on day 4 and day 30 (normal value, 
>135 mmol per liter; mild hyponatremia, 130 to 
135 mmol per liter as conservatively extended for 
the analysis of categorical change; or marked hy-
ponatremia, <130 mmol per liter) for patients with 
mild or marked hyponatremia at baseline. Other 
secondary end points were fluid intake and out-
put on day 1, change in body weight in patients 
with hypervolemic hyponatremia on day 1, fluid 
restriction or use of intravenous saline as rescue 
therapy, and the change from baseline in scores 
on the Physical Component Summary and Men-
tal Component Summary of the Medical Outcomes 
Study 12-item Short-Form (SF-12) General Health 
Survey.
Adverse events were defined as any new medi-
cal problem or exacerbation of an existing medical 
problem in a patient enrolled in the study. Pa-
tients could spontaneously report such events to 
an investigator. In addition, at each visit, inves-
tigators asked patients the nonleading question, 
“How have you felt since your last visit?” Each 
investigator was required to assess and report to 
the sponsor the seriousness and severity of each 
event and whether the event was probably asso-
ciated with the study drug. The sponsor then re-
ported such events to the appropriate regulatory 
authorities and to the study’s independent safety 
oversight committee.
Statistical Analysis
The change in the average daily AUC for the serum 
sodium concentration from baseline to day 4 and 
from baseline to day 30 (the two primary end 
points) was calculated as the AUC for each pa-
tient, divided by the observation period (4 or 30 
days), minus the baseline value. The sodium 
changes in the two study groups were compared 
with an analysis of covariance (ANCOVA) model 
in which the group assignment and baseline strat-
ification factors were covariates. We calculated 
that a sample of 100 patients per group would 
yield more than 90% power (with a two-sided 
Figure 1 (facing page). Enrollment, Randomization, 
and Follow-up of Patients in the SALT-1 (Panel A) 
and SALT-2 (Panel B) Trials.
Patients who received at least one dose of the study 
medication (tolvaptan or placebo) were included in the 
safety analysis. Patients whose serum sodium concentra-
tions were evaluated at baseline and one or more times 
after baseline were included in the efficacy analysis. 
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244 Patients underwent screening
205 Met inclusion criteria
102 Assigned to tolvaptan
15 mg daily
103 Assigned to placebo
15 mg daily
Increased to 30 mg or 60 mg,
if necessary
Increased to 30 mg or 60 mg,
if necessary
100 Included in safety analysis
95 Included in efficacy analysis
101 Included in safety analysis
89 Included in efficacy analysis
79 Completed 30-day study period
and 7-day follow-up
65 Completed 30-day study period
and 7-day follow-up
23 Withdrew 38 Withdrew
304 Patients underwent screening
243 Met inclusion criteria
123 Assigned to tolvaptan
15 mg daily
120 Assigned to placebo
15 mg daily
Increased to 30 mg or 60 mg,
if necessary
Increased to 30 mg or 60 mg,
if necessary
123 Included in safety analysis
118 Included in efficacy analysis
119 Included in safety analysis
114 Included in efficacy analysis
92 Completed 30-day study period
and 7-day follow-up
89 Completed 30-day study period
and 7-day follow-up
31 Withdrew 31 Withdrew
A
B
SALT-1
SALT-2
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significance level of 0.025) to detect a mean (±SD) 
between-group difference of 1.99±2.7 mmol of 
sodium per liter in the change from baseline to 
day 4 and of 3.00±3.28 mmol of sodium per liter 
from baseline to day 30. With similar assump-
tions, we calculated that the inclusion of 50 pa-
tients with marked hyponatremia in each group 
would yield 90% power (with a two-sided sig-
nificance level of 0.05). To preserve an overall 
nominal significance level of 0.05 for each of the 
primary end points, the Hochberg procedure was 
prespecified.15
Serum sodium concentrations were compared 
between study groups with the use of the ANCOVA 
model and the covariates noted above. The per-
centage of patients in whom serum sodium con-
centrations normalized (>135 mmol per liter) or 
fluid restriction was used was analyzed with the 
Cochran–Mantel–Haenszel test and the baseline 
stratification factors. We compared shifts in the 
categorical change in hyponatremia in the two 
groups with the use of the Cochran–Mantel–
Haenszel mean score test, using a modified ridit 
score (van Elteren test), with cause as a stratifi-
cation factor. This analysis was performed sepa-
rately for subgroups of patients classified at base-
line as having mild hyponatremia (a serum sodium 
concentration of 130 to 134 mmol per liter) or 
marked hyponatremia (<130 mmol per liter). Cat-
egories after treatment were defined as normal, 
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Figure 2. Change in the Average Daily Area under the Curve (AUC) for the Serum Sodium Concentration from Base-
line to Day 4 (Panel A) and from Baseline to Day 30 (Panel B). 
P<0.001 for all comparisons. HN denotes hyponatremia.
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Table 2. Results of Efficacy Analysis.*
Variable SALT-1 SALT-2
Tolvaptan
(N = 102)
Placebo
(N = 103) P Value
Tolvaptan
(N = 123)
Placebo
(N = 120) P Value
Primary end point: change in average AUC for 
serum sodium — mmol/liter
All patients
Day 4 3.62±2.68 0.25±2.08 <0.001 4.33±2.87 0.42±2.56 <0.001
Day 30 6.22±4.10 1.66±3.59 <0.001 6.20±3.92 1.84±3.83 <0.001
Mild hyponatremia
Day 4 2.52±1.95 −0.32±2.27 <0.001 3.59±2.34 0.18±2.01 <0.001
Day 30 3.87±3.01 0.68±2.78 <0.001 4.68±2.91 0.94±2.89 <0.001
Marked hyponatremia
Day 4 4.56±2.88 0.76±1.77 <0.001 5.06±3.16 0.7±2.99 <0.001
Day 30 8.24±3.84 2.54±4.01 <0.001 7.60±4.31 2.72±4.41 <0.001
Absolute change in serum sodium — mmol/liter
Baseline 128.5±4.5 128.7±4.1 129.±3.5 128.9±4.5
Day 4
Mean 133.9±4.8 129.7±4.9 <0.001 135.3±3.6 129.6±5.2 <0.001
No. of patients 95 88 115 112
Day 30
Mean 135.7±5.0 131.0±6.2 <0.001 135.9±5.9 131.5±5.7 <0.001
No. of patients 95 89 114 98
Categorical change in hyponatremia — 
no./total no. (%)
Baseline
Mild hyponatremia 49/102 (48) 51/103 (50) 64/123 (52) 62/120 (52)
Marked hyponatremia 53/102 (52) 52/103 (50) 59/123 (48) 58/120 (48)
Day 4
Normal 38/95 (40) 12/89 (13) <0.001 65/118 (55) 12/114 (11) <0.001
Marked hyponatremia 12/95 (13) 44/89 (49) <0.001 12/118 (10) 46/114 (40) <0.001
Day 30
Normal 50/95 (53) 22/89 (25) <0.001 69/118 (58) 28/114 (25) <0.001
Marked hyponatremia 7/95 (7) 31/89 (35) <0.001 18/118 (15) 37/114 (32) 0.002
Fluid status
Urine output on day 1 — ml 3218±1646 2076±1534 <0.001 3185±2543 1914±1366 <0.001
Fluid intake on day 1 — ml 1825±1057 1492±945 0.04 2129±2110 1705±1396 0.09
Difference on day 1 — ml −1533±1429 −636±1275 <0.001 −1059±1877 −185±870 <0.001
Patients requiring fluid restriction — % 9.3 17.5 0.08 9.2 16.8 0.08
* The range for mild hyponatremia, defined as a baseline serum sodium concentration of 130 to 134 mmol per liter, was conservatively ex-
tended to 130 to 135 mmol per liter for the analysis of categorical change. Marked hyponatremia was defined as a serum sodium concentra-
tion of less than 130 mmol per liter. Patients whose serum sodium concentrations were evaluated at baseline and one or more times after 
baseline were included in the efficacy analysis. P values are for the comparison of the change in serum sodium concentrations from base-
line to day 4 and from baseline to day 30 between the placebo group and the tolvaptan group. Plus–minus values are means ±SD. AUC de-
notes area under the curve. 
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mild, and marked, as described above, with the 
range for mild conservatively extended to a se-
rum sodium concentration of 135 mmol per liter 
for this analysis.16
The time to normalization of the serum sodi-
um concentration was analyzed with the use of a 
log-rank test. Fluid loss, fluid intake, and fluid 
balance (total intake minus total output) on day 
1 were evaluated with the use of an analysis-of-
variance model, with the assigned study group 
and baseline stratification factors as covariates.
The Physical Component Summary and Men-
tal Component Summary scales of the SF-12 
Health Survey (ranges, 5 to 69 for the physical 
component and 8 to 73 for the mental compo-
nent, with higher scores indicating better func-
tioning) were derived with the use of weights 
provided in the SF-12 Health Survey manual.17 
The SF-12 Health Survey was chosen as a patient-
reported outcome for overall health status be-
cause it has been validated in numerous clinical 
studies. The physical component assesses physical 
functioning, bodily pain, physically limited accom-
plishment, and general health, and the mental 
component assesses vitality, social functioning, 
emotionally limited accomplishment, calmness, 
and sadness. The absolute shift from baseline of 
5 units was considered a clinically important dif-
ference.18 Changes from baseline scores were ana-
lyzed in the pooled database of the SALT-1 and 
SALT-2 trials with an ANCOVA model, with the 
assigned study group, baseline stratification fac-
tors, and baseline scores as covariates. All reported 
P values are two-sided.
 The development of the protocol and the 
data analysis were undertaken jointly by the 
sponsor, the investigators, and the authors. Dr. 
Schrier assumes responsibility for the overall 
content and integrity of the manuscript, with 
substantial contributions from the coauthors; all 
authors vouch for the accuracy and completeness 
of the reported data. There was no interim 
analysis. The sponsor holds the data, which are 
freely available.
R esult s
In the SALT-1 and SALT-2 trials, 102 and 123 pa-
tients, respectively, were assigned to tolvaptan 
and 103 and 120, respectively, were assigned to 
placebo. The demographic and baseline charac-
teristics of the patients were similar in the study 
groups in both trials (with the exception of a sig-
nificant difference in height in SALT-1). Patients 
enrolled in the trials had similar diverse causes 
of hyponatremia (Table 1).
In SALT-1, 79 (77.5%) of the 102 patients as-
signed to tolvaptan and 65 (63.1%) of the 103 pa-
tients assigned to placebo completed the 30-day 
study period and the 7-day follow-up (Fig. 1A). In 
SALT-2, 92 (74.8%) of the 123 patients assigned to 
tolvaptan and 89 (74.2%) of the 120 patients as-
signed to placebo completed the trial (Fig. 1B).
Efficacy
The increase in the average daily AUC for the se-
rum sodium concentration was significantly great-
er in the tolvaptan group than in the placebo 
group from baseline to study day 4 as well as dur-
ing the entire 30-day study period (Fig. 2A and 2B 
and Table 2). Tolvaptan was also associated with 
a significantly greater increase in the average dai-
ly AUC for the serum sodium concentration in 
subgroups stratified according to whether hypo-
natremia was mild or marked at baseline.
Serum sodium concentrations over the course 
of the trial are shown in Figure 3. Within 8 hours 
after the first administration of tolvaptan, the 
serum sodium concentrations were significantly 
higher in the tolvaptan group than in the placebo 
group for both the total patient population and 
the subgroups stratified according to the degree 
of hyponatremia at baseline. This statistical su-
periority was maintained at all subsequent visits 
during the study period within all stratification 
subgroups. The serum sodium concentration ap-
proached the normal range more rapidly in the 
tolvaptan group than in the placebo group. Dur-
ing the follow-up week after discontinuation of 
the study drug, there was no statistical difference 
in the decline in serum sodium concentrations 
between the two groups.
In both SALT-1 and SALT-2, significantly more 
Figure 3 (facing page). Mean Serum Sodium Concen-
trations According to the Day of Patient Visit.
Asterisks indicate P<0.001 for the comparison between 
tolvaptan and placebo. Daggers indicate P<0.01 for the 
comparison between tolvaptan and placebo. Tolvaptan 
was discontinued on day 30. Circles denote patients re-
ceiving tolvaptan, and squares denote patients receiv-
ing placebo. Horizontal lines indicate the lower limit of 
the normal range for the serum sodium concentration. 
Vertical lines indicate the end of the treatment period. 
HN denotes hyponatremia. 
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patients assigned to tolvaptan had normal serum 
sodium concentrations on day 4 and on day 30 
than did patients assigned to placebo (Table 2). 
Similarly, in both trials, significantly fewer pa-
tients in the tolvaptan group had marked hypo-
natremia on day 4 and on day 30 (Table 2).
The difference between urine production and 
fluid intake during the first day was significantly 
greater in the tolvaptan group than in the pla-
cebo group (Table 2). Among patients assigned to 
tolvaptan in the combined population of the two 
studies and in the subgroups with marked hypo-
natremia in both studies, the trend was toward 
requiring less fluid restriction (P = 0.08 for each 
study). Neither outpatient fluid intake nor urine 
osmolality was measured.
The effect of the study drugs on self-assessed 
health status was determined on day 30 in a pre-
specified combined analysis of scores for the 
Physical Component Summary and the Mental 
Component Summary of the SF-12 Health Survey 
(Fig. 1 of the Supplementary Appendix, available 
with the full text of this article at www.nejm.org). 
Scores on the Physical Component Summary did 
not differ significantly between groups, but those 
for the Mental Component Summary improved in 
the tolvaptan group in the combined analysis 
(P = 0.02) and in SALT-1 (P = 0.04), although not 
in SALT-2 (P = 0.14). Scores for the Mental Com-
ponent Summary improved significantly in the 
combined subgroup of patients with marked hy-
ponatremia (P = 0.04).
adverse events and safety
Adverse event profiles in the two study groups 
were similar for all intratrial and intertrial com-
Table 3. Adverse Events.*
Variable SALT-1 SALT-2
Tolvaptan
(N = 100)
Placebo
(N = 101)
Tolvaptan
(N = 123)
Placebo
(N = 119)
Total patient-days of drug exposure 2669 2292 3228 3055
no. of patients (%)
Adverse events occurring during study (all causes) 88 (88) 83 (82) 91 (74) 85 (71)
Serious adverse events 31 (31) 35 (34) 33 (27) 30 (25)
Withdrawal because of adverse events 9 (9) 17 (17) 14 (11) 9 (8)
Adverse events (potentially study-related) 50 (50) 34 (34) 42 (34) 29 (24)
Serious adverse events 2 (2)† 6 (6)‡ 6 (5)§ 4 (3)¶
Withdrawal because of adverse events 4 (4)∥ 7 (7)** 4 (3)†† 1 (1)‡‡
Tolvaptan Group
(N = 223)
Placebo Group
(N = 220)
Common adverse events — body system and MedDRA 
preferred term§§
Gastrointestinal disorders
Ascites 14 (6) 13 (6)
Constipation 16 (7) 4 (2)
Diarrhea (not organ-specific) 12 (5) 12 (6)
Dry mouth 28 (13) 9 (4)
Nausea 18 (8) 13 (6)
Vomiting (not organ-specific) 7 (3) 19 (9)
General disorders
Fatigue 12 (5) 11 (5)
Peripheral edema 16 (7) 15 (7)
Thirst 32 (14) 10 (5)
Weakness 21 (9) 10 (5)
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parisons (Table 3). The most common adverse 
events occurring during the study in the tolvaptan 
groups were thirst and dry mouth. Overall, there 
were 26 serious adverse events potentially related 
to the study treatment in SALT-1 and SALT-2. Elev-
en occurred in 8 patients assigned to tolvaptan 
(dehydration with hypotension, dehydration with 
dizziness, syncope, acute renal failure, ascites, 
increased serum sodium and creatinine concen-
trations and Escherichia coli sepsis with respiratory 
failure in 1 patient each), and 15 occurred in 10 
patients assigned to placebo (acute renal failure 
in 2 patients, rash in 2 patients, aggravated cardiac 
failure [twice in 1 patient], and acute dyspnea with 
edema, worsened anemia with increased serum 
creatinine concentration and decreased hemoglo-
bin and hematocrit, vomiting, hepatic encepha-
lopathy, and dyspepsia in 1 patient each). Eight 
patients in the tolvaptan group withdrew because 
of adverse events that were potentially related to 
the study treatment (rash in two patients and dys-
geusia, nocturia, urinary frequency, exanthema, 
muscle weakness, and hypernatremia in one pa-
tient each), as well as eight patients in the placebo 
group (rash in two patients, acute renal failure in 
two patients, and increased serum creatinine con-
centration, decreased serum sodium concentra-
tion, aggravated hyponatremia, and vomiting in 
one patient each). The number of deaths in the 
two study groups was similar (14 deaths among 
223 patients in the tolvaptan groups and 13 deaths 
among 220 patients in the placebo groups), and 
they occurred within the defined observation 
period. 
In only 4 of the 223 patients in the tolvaptan 
group were desirable rates of sodium correction 
exceeded during the first 24 hours of the study 
(>0.5 mmol per liter per hour; maximum observed 
rate, 0.61 mmol per liter per hour). In only four 
patients (1.8%) was the predefined, potentially 
clinically important serum sodium concentration 
(>146 mmol per liter) exceeded.
Table 3. (Continued.)
Variable
Tolvaptan Group
(N = 223)
Placebo Group
(N = 220)
Infections and infestations
Urinary tract infection (not organ-specific) 13 (6) 8 (4)
Metabolism and nutritional disorders
Hyperglycemia (not organ-specific) 12 (5) 2 (1)
Hyperkalemia 12 (5) 11 (5)
Nervous system disorders
Dizziness 15 (7) 11 (5)
Headache (not organ-specific) 15 (7) 15 (7)
Renal and urinary tract disorders
Urinary frequency 15 (7) 6 (3)
Vascular disorders
Hypotension (not organ-specific) 15 (7) 14 (6)
* Patients who received at least one dose of the study medication (tolvaptan or placebo) were included in the safety analysis. MedDRA de-
notes the Medical Dictionary for Regulatory Activities.
† Serious adverse events in this group included dehydration with hypotension (1 patient) and increased serum creatinine concentrations.
‡ Serious adverse events in this group included acute renal failure (2 patients), rash (2 patients), cardiac failure (twice in 1 patient), and 
vomiting.
§ Serious adverse events in this group included dehydration with dizziness (1 patient), syncope, acute renal failure, ascites, increased serum 
sodium concentrations, Escherichia coli sepsis, and respiratory failure (1 patient).
¶ Serious adverse events in this group included hepatic encephalopathy, acute dyspnea and edema (1 patient), worsening anemia, increased 
serum creatinine concentrations with lower hemoglobin and hematocrit values, and dyspepsia (1 patient).
∥ Serious adverse events in this group included rash (2 patients) and nocturia.
** Serious adverse events in this group included rash (2 patients), acute renal failure (2 patients), dysgeusia, decreased serum sodium concen-
trations, vomiting, and aggravated hyponatremia. 
†† Serious adverse events in this group included urinary frequency, exanthema, muscle weakness, and hypernatremia.
‡‡ The serious adverse event in this group was increased serum creatinine concentration.
§§ Common adverse events are defined as events occurring in more than 5% of patients.
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Discussion
We examined the use of an orally active vasopres-
sin V2-receptor antagonist for 30 days to correct 
and maintain serum sodium concentrations in a 
population with hyponatremia from various causes 
(e.g., chronic heart failure, cirrhosis, and SIADH). 
Previous, short-term studies have shown that va-
sopressin V2-antagonists correct hyponatremia 
in patients with chronic heart failure,11,19 cirrho-
sis,20 or SIADH.21 A long-term study examined 
the effects of tolvaptan in patients with chronic 
heart failure,12 but the primary end point was the 
change in body weight, not correction of hypona-
tremia. 
The present study was conducted primarily in 
the outpatient setting, without mandated fluid 
restriction or a change in the patient’s medication 
regimen, such as use of diuretics, to treat the 
patient’s primary disease. Tolvaptan was superi-
or to placebo with respect to several measures, 
including the change in the average daily AUC 
for serum sodium concentrations from baseline 
to day 4 and from baseline to day 30, the mean 
serum sodium concentration at each visit, the 
time to normalized serum sodium concentrations, 
the percentage of patients with serum sodium 
concentrations that were normal on day 4 and on 
day 30, and the categorical change in the serum 
sodium concentration from baseline to day 4 and 
from baseline to day 30. Tolvaptan was superior to 
placebo from the first observation point (8 hours) 
after administration of the first dose until the last 
treatment day (day 30) in patients with either mild 
or marked hyponatremia and among patients with 
hyponatremia from all major causes. During the 
7-day follow-up period, serum sodium concentra-
tions reverted to degrees of hyponatremia that 
were equivalent to those associated with the use 
of placebo, indicating that the aquaretic effect of 
tolvaptan (excretion of electrolyte-free water) was 
required to maintain normal sodium concentra-
tions in patients with chronic hyponatremia.
Hyponatremia occurs in 15 to 20% of hospi-
talized patients and constitutes a common se-
rum electrolyte abnormality.22 Hyponatremia is 
reported to be an independent predictor of com-
plications and death in patients with heart dis-
ease,23,24 cirrhosis,6 or neurologic disorders.8 Re-
cent clinical data suggest that hyponatremia not 
only is a marker of disease severity but also con-
tributes to illness, even in patients with mild 
chronic hyponatremia, increasing the risk of falls 
and cognitive dysfunction.9 This factor is particu-
larly relevant given the aging population in the 
United States and the high prevalence of hypo-
natremia reported among residents of nursing 
homes.25 Current approaches to the treatment of 
hyponatremia are suboptimal, have variable ef-
ficacy, have slow responses, are poorly tolerated, 
and have important side effects.26,27 Thus, recent 
limited regulatory approval of the vasopressin an-
tagonists mozavaptan in Japan (oral OPC-31260, 
for paraneoplastic SIADH [Physuline, Otsuka Phar-
maceutical]) and conivaptan in the United States 
(parenteral formulation, for hospitalized patients 
with euvolemic SIADH [Vaprisol, Astellas Pharma]) 
are promising for the management of hypona-
tremia.21,28 Despite the approval of these drugs, 
it is not known whether treating hyponatremia 
alone will result in a long-term survival benefit.
In addition to assessing the efficacy of tolvap-
tan for increasing serum sodium concentrations, 
its effect on scores on the SF-12 Health Survey 
was examined. There was no significant effect on 
scores for the Physical Component Summary of 
the survey. However, there was a demonstrable 
effect on scores for the Mental Component Sum-
mary (for vitality, social functioning, emotionally 
limited accomplishment, calmness, and sadness). 
The size of the effect on scores for the Mental 
Component Summary would be considered clin-
ically significant.18
These two month-long trials of efficacy and 
safety in the treatment of hyponatremia suggest 
that the vasopressin V2-receptor antagonist tolvap-
tan, when added to standard therapy, was superior 
to placebo in raising and maintaining serum so-
dium concentrations in patients with euvolemic 
or hypervolemic hyponatremia of diverse origin. 
Tolvaptan had side effects that were consistent 
with its physiological activity. The dose could be 
increased gradually to achieve the desired rate 
and the desired degree of serum sodium correc-
tion in most patients.
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